Elevance Health (ELV): +18% Surge in 30 Days on Earnings Strength and Raised Guidance
Key Takeaways
- ELV stock surged +18% over the last 30 days, driven primarily by a strong Q1 2026 earnings beat and raised full-year guidance.
- Over the past quarter, the stock rose +10%, recovering from earlier Medicaid and Medicare pressures amid improving sector sentiment.
- Key catalysts include robust EPS of $12.58 (beating estimates by 16%), upgraded analyst ratings, and positive Medicare Advantage rate news.
- Health Benefits segment showed stronger premium yields; CarelonRx revenue growth supported topline.
- Challenges like Medicaid margins persist but are offset by cost controls and membership stability.
Understanding Elevance Health (ELV) and Its Market Position
Elevance Health, Inc. (ELV) stands as a leading health benefits company in the United States, delivering a broad array of health plans and services. It serves roughly 47 million medical members across segments like Health Benefits, CarelonRx for pharmacy services, Carelon Services for behavioral and specialty care, and Corporate & Other. The core model centers on managed care, encompassing HMOs, PPOs, Medicare, Medicaid, and fee-based administrative services, with revenue flowing mainly from premiums, pharmacy services, and care management fees.
In the competitive landscape of U.S. health insurance, ELV maintains a robust position as one of the largest for-profit managed care organizations tied to the Blue Cross Blue Shield Association. Main rivals include UnitedHealth Group (UNH), Cigna Group (CI), Humana (HUM), and Centene (CNC). From what I see, the company's scale, diversified revenues, and emphasis on value-based care plus digital tools like HealthOS give it real resilience—it's why ELV has managed to rebound from sector challenges through solid operations and membership gains.
ELV Stock Performance: 30-Day Climb vs. Quarterly Gain
In the last 30 days, ELV stock has advanced +18%, shifting from about $312 to around $369. This move has been trend-led but volatile, featuring a sharp post-earnings jump on April 23 after the Q1 release—shares rose over 17% in that single session—followed by consolidation at higher levels alongside analyst upgrades.
Looking at the past quarter, the stock posted a +10% gain, from roughly $338 to $369. Early on, it traded in a range amid Medicaid cost worries, but momentum built steadily after early April Medicare rate news and the earnings trigger, mirroring a wider lift in managed care names.
Key Drivers Behind ELV's 30-Day Stock Rally
The standout catalyst here was Elevance Health's Q1 2026 earnings on April 22, with adjusted EPS at $12.58—beating consensus of $10.74 by 16%—and revenue of $49.5 billion, up 1.5% year-over-year and above expectations. Management lifted full-year 2026 adjusted EPS guidance to at least $26.75 from $25.50, pointing to business momentum, better claims trends, and cost discipline, even with a $935 million CMS risk adjustment accrual.
Premium yields strengthened in Health Benefits, while CarelonRx posted revenue growth. I also checked this using Tickeron’s AI Screener to gauge how ELV stacks up against peers in the space. Analysts piled on with upgrades, like Bank of America's Buy call and $435 target on April 29, citing a Medicaid margin bottom and upside potential. Sector tailwinds from a 2.48% Medicare Advantage rate hike for 2027 added fuel, easing regulatory strains and brightening profit prospects.
Factors Shaping ELV's Quarterly Performance
The quarter's +10% rise ties into a larger story of stabilization for managed care amid pressures like rising medical costs and membership flux. Initial softness came from Medicaid margins compressing to about 2x historical norms, plus a high-teens drop in Medicare Advantage risk-based membership, layered with CMS sanction concerns.
One thing that stands out is how recovery took hold through sector progress, such as finalized Medicare rates offering some breathing room, and ELV's steady cash flow outlook of at least $5.5 billion. Post-earnings, institutional interest picked up, with $1.5 billion returned to shareholders via buybacks and dividends. Carelon's external revenue expansion and AI-fueled efficiencies bolstered its edge, tipping the scales positively despite inflation and regs.
Exploring Tickeron’s Trending AI Robots
In my own trading and research, I often turn to Tickeron’s Trending AI Robots page, which spotlights the platform's strongest performers among hundreds of bots trading thousands of tickers across markets. It curates bots based on recent results, market relevance, and metrics like win rate, average return, and Sharpe ratio—covering everything from intraday momentum to weekly trend strategies. I find it useful to review profiles, backtests, live data, and options to potentially automate parts of my approach. If you're looking to add AI-driven tools to your process, this page is worth a visit for bots that might align with your style.
What to Watch in ELV Stock Moving Forward
I'm watching the Q2 2026 earnings closely for insight into EPS progress toward that $26.75+ full-year goal and Medicaid margin trends. Keep an eye on Medicare Advantage enrollment for 2027 and value-based care shifts, as they'll shape sentiment. Broader elements like interest rates, inflation on med costs, and CMS rules stay pivotal. Progress in Carelon Services growth and AI for claims could unlock more efficiency. On the flip side, watch for ongoing utilization spikes, CMS audits, or competition; upsides might come from membership adds or fresh upgrades. This is important because it frames the risks and opportunities ahead for ELV.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
ELV sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for ELV moved above the 200-day moving average on May 18, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ELV advanced for three days, in of 315 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 214 cases where ELV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for ELV moved out of overbought territory on May 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 66 cases where ELV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on June 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ELV as a result. In of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ELV turned negative on May 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.935) is normal, around the industry mean (3.872). P/E Ratio (16.579) is within average values for comparable stocks, (39.073). Projected Growth (PEG Ratio) (1.432) is also within normal values, averaging (1.218). Dividend Yield (0.018) settles around the average of (0.021) among similar stocks. P/S Ratio (0.435) is also within normal values, averaging (0.553).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. ELV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of life, hospital and medical insurance plans
Industry ManagedHealthCare
Advertisement